Pharmacologic Therapy of Non-Alcoholic Steatohepatitis

Vlad Ratziu, Shira Zelber-Sagi

Research output: Contribution to journalReview articlepeer-review


Specific therapy for non-alcoholic steatohepatitis (NASH) is needed because of the potential severity of this liver disease. NASH is a recognized cause of cryptogenic cirrhosis and, increasingly, of hepatocellular carcinoma. Therefore, there is an unmet medical need for the therapy of NASH. This article discusses this therapy, with particular emphasis on pharmacologic therapy.

Original languageEnglish
Pages (from-to)667-688
Number of pages22
JournalClinics in Liver Disease
Issue number4
StatePublished - Nov 2009


  • Fibrosis
  • Glitazones
  • Hepatoprotectants
  • Non-alcoholic steatohepatitis
  • Orlistat
  • Sartans
  • Steatosis
  • Ursodesoxycholic acid

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Pharmacologic Therapy of Non-Alcoholic Steatohepatitis'. Together they form a unique fingerprint.

Cite this